NEOGENOMICS INC

NeoGenomics insider sale sparks debate: insider buying outweighs selling, capital raise for lab expansion, clinical impact on oncology diagnostics, and regulatory risks for investors.

NeoGenomics insider buying surge signals confidence in its growing diagnostics revenue and AI‑driven expansion, but investors should watch P/E, dilution, and payer contracts before buying or holding.

NeoGenomics insider buying, defense partnership, and FDA battery approval reveal a dual‑growth strategy poised to boost diagnostics and defense revenue—key insights for investors.

NeoGenomics insider Greg Aunan’s March 2026 option and RSU purchases show confidence in the company’s new RaDaR ST platform and long‑term upside, despite recent price dips and negative earnings.

NeoGenomics CFO receives new 3‑year stock‑option award tied to rising share price, reflecting confidence in the RaDaR ST ctDNA platform’s growth potential.